Compare Quest Diagnostics Inc (DGX) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Five Below Inc — how do they compare? Quest Diagnostics Inc trades at $230.89 (market cap $25.48B), while Five Below Inc trades at $215.81 (market cap $11.55B). The key difference: Quest Diagnostics Inc is far larger — about 2.2× Five Below Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Five Below Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Five Below Inc for 46 Days on average.
| DGX | FIVE | |
|---|---|---|
Market Cap | $25.48B | $11.55B |
Volume | 941,866 | 1,120,554 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $262.72 |
52-Week Low | $173.49 | $138.49 |
Typical Hold Time | 56 Days | 46 Days |
Enterprise Value | $31.23B | $12.40B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Five Below (FIVE) trades at $213.30, up 4.44% today, with strong earnings beats in recent quarters and a bullish analyst consensus of 60% buy ratings. The stock shows bearish technical signals but maintains solid fundamentals with 40.26% gross margins and 28.25% ROE. Recent news highlights growth initiatives including a $600 million buyback and board appointments.
Outlook remains positive with revenue projected to grow to $5.3 billion in 2026 and net income margin improving to 11.65%. Risks include premium valuation (P/E 18.81) and execution pressure amid economic headwinds. The consensus price target of $298.44 suggests 40% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
